Sara Coca Membribes, Clinical Research Fellow at Barts Health NHS Trust, shared a post on X:
“Big day for RCC: 2 positive belzutifan combo studies
– Belzutifan + pembro (adjuvant): DFS
– Belzutifan + lenvatinib (pretreated mx): PFS
Well tolerated & promising partner but is combining better than sequencing? Will EMA need OS?”
You Can Also Read: LITESPARK-015: Belzutifan shows durable activity with manageable safety in advanced PPGL
